RxDoctor Payments Data

Tara Dwelley

Family · Princeton, MENPI 1780649137

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $405, 2.2 times the $181 reported in 2021. Among family clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,527in general payments, 2019–2025

Across 88 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$260
  • Novo Nordisk$186
  • GSK$162
  • Lundbeck LLC$158
  • AstraZeneca$121
  • Sanofi-aventis U.S. LLC$88
  • plus $553 from 17 others

What the payments were for

  • Food & beverage$1,51399%
  • Other$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,527 in reported general payments places this provider in the 90th percentile of 545 family providers in Maine.

See all family providers in Maine

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$78,398
OzempicSemaglutide42$46,245
EliquisApixaban37$43,260
JardianceEmpagliflozin26$41,840
FarxigaDapagliflozin Propanediol33$38,597
MounjaroTirzepatide17$19,046
RybelsusSemaglutide14$17,547
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$17,032
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$15,428
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl65$7,985
Advair HfaFluticasone Propion/Salmeterol12$6,899
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$4,613
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$4,320
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen168$3,793
Pregabalin49$2,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arnuity Ellipta$162$80,63092 claims
Novo NordiskOzempic, Rybelsus$186$63,79256 claims
AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere$121$60,24361 claims
PfizerEliquis$260$43,26037 claims
Boehringer IngelheimJardiance$35$41,84026 claims
Lilly USA, LLCMounjaro$50$19,04617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 545 family providers in Maine.

Other family in Princeton

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →